Literature DB >> 24962146

Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Matthew J Weiss1, David Cosgrove, Joseph M Herman, Neda Rastegar, Ihab Kamel, Timothy M Pawlik.   

Abstract

Cholangiocarcinoma (CCA) is the second most common primary malignancy of the liver arising from malignant transformation and growth of biliary ductal epithelium. Approximately 50-70 % of CCAs arise at the hilar plate of the biliary tree, which are termed hilar cholangiocarcinoma (HC). Various staging systems are currently employed to classify HCs and determine resectability. Depending on the pre-operative staging, the mainstays of treatment include surgery, chemotherapy, radiation therapy, and photodynamic therapy. Surgical resection offers the only chance for cure of HC and achieving an R0 resection has demonstrated improved overall survival. However, obtaining longitudinal and radial surgical margins that are free of tumor can be difficult and frequently requires extensive resections, particularly for advanced HCs. Pre-operative interventions may be necessary to prepare patients for major hepatic resections, including endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography, and portal vein embolization. Multimodal therapy that combines chemotherapy with external beam radiation, stereotactic body radiation therapy, bile duct brachytherapy, and/or photodynamic therapy are all possible strategies for advanced HC prior to resection. Orthotopic liver transplantation is another therapeutic option that can achieve complete extirpation of locally advanced HC in judiciously selected patients following standardized neoadjuvant protocols.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24962146     DOI: 10.1007/s00423-014-1219-1

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  134 in total

1.  Klatskin tumors and the accuracy of the Bismuth-Corlette classification.

Authors:  Andreas Paul; Gernot M Kaiser; Ernesto P Molmenti; Tobias Schroeder; Spiridon Vernadakis; Arzu Oezcelik; Hideo A Baba; Vito R Cicinnati; Georgios C Sotiropoulos
Journal:  Am Surg       Date:  2011-12       Impact factor: 0.688

Review 2.  Liver transplantation for cholangiocarcinoma.

Authors:  Charles B Rosen; Julie K Heimbach; Gregory J Gores
Journal:  Transpl Int       Date:  2010-05-20       Impact factor: 3.782

3.  Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection.

Authors:  Helmut Witzigmann; Frieder Berr; Ulrike Ringel; Karel Caca; Dirk Uhlmann; Konrad Schoppmeyer; Andrea Tannapfel; Christian Wittekind; Joachim Mossner; Johann Hauss; Marcus Wiedmann
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

4.  Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma.

Authors:  A Kobayashi; S Miwa; T Nakata; S Miyagawa
Journal:  Br J Surg       Date:  2010-01       Impact factor: 6.939

5.  Surgical resection for hilar cholangiocarcinoma: experience improves resectability.

Authors:  Robert M Cannon; Guy Brock; Joseph F Buell
Journal:  HPB (Oxford)       Date:  2011-12-12       Impact factor: 3.647

6.  Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach.

Authors:  Emmanuel E Zervos; Dana Osborne; Steven B Goldin; Desiree V Villadolid; Donald P Thometz; Alan Durkin; Larry C Carey; Alexander S Rosemurgy
Journal:  Am J Surg       Date:  2005-11       Impact factor: 2.565

7.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

8.  Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy.

Authors:  Hiroaki Shimizu; Fumio Kimura; Hiroyuki Yoshidome; Masayuki Ohtsuka; Atsushi Kato; Hideyuki Yoshitomi; Katsunori Furukawa; Masaru Miyazaki
Journal:  Ann Surg       Date:  2010-02       Impact factor: 12.969

Review 9.  Hilar cholangiocarcinoma: role of preoperative imaging with sonography, MDCT, MRI, and direct cholangiography.

Authors:  Jin-Young Choi; Myeong-Jin Kim; Jeong Min Lee; Ki Whang Kim; Jae Young Lee; Joon Koo Han; Byung Ihn Choi
Journal:  AJR Am J Roentgenol       Date:  2008-11       Impact factor: 3.959

10.  Local surgical resection of hilar cholangiocarcinoma: is there still a place?

Authors:  L Capussotti; L Vigano; A Ferrero; A Muratore
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

View more
  10 in total

1.  Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging.

Authors:  Jimme K Wiggers; Bas Groot Koerkamp; David van Klaveren; Robert J Coelen; C Yung Nio; Peter J Allen; Marc G Besselink; Olivier R Busch; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Thomas M van Gulik; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2018-04-06       Impact factor: 6.113

2.  Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.

Authors:  Xu-Feng Zhang; Eliza W Beal; Jeffery Chakedis; Qinyu Chen; Yi Lv; Cecilia G Ethun; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

Review 3.  Perioperative Management of Hilar Cholangiocarcinoma.

Authors:  Katherine E Poruk; Timothy M Pawlik; Matthew J Weiss
Journal:  J Gastrointest Surg       Date:  2015-05-29       Impact factor: 3.452

4.  Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer.

Authors:  Gaya Spolverato; Fabio Bagante; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Emily Winslow; Clifford Cho; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

5.  The Interplay Between Biliary Occlusion and Liver Regeneration: Repeated Regeneration Stimuli Restore Biliary Drainage by Promoting Hepatobiliary Remodeling in a Rat Model.

Authors:  Beate Richter; Constanze Sänger; Franziska Mussbach; Hubert Scheuerlein; Utz Settmacher; Uta Dahmen
Journal:  Front Surg       Date:  2022-04-25

6.  Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases.

Authors:  Chihua Fang; Jihyun An; Antonio Bruno; Xiujun Cai; Jia Fan; Jiro Fujimoto; Rita Golfieri; Xishan Hao; Hongchi Jiang; Long R Jiao; Anand V Kulkarni; Hauke Lang; Cosmas Rinaldi A Lesmana; Qiang Li; Lianxin Liu; Yingbin Liu; Wanyee Lau; Qiping Lu; Kwan Man; Hitoshi Maruyama; Cristina Mosconi; Necati Örmeci; Michael Pavlides; Guilherme Rezende; Joo Hyun Sohn; Sombat Treeprasertsuk; Valérie Vilgrain; Hao Wen; Sai Wen; Xianyao Quan; Rafael Ximenes; Yinmo Yang; Bixiang Zhang; Weiqi Zhang; Peng Zhang; Shaoxiang Zhang; Xiaolong Qi
Journal:  Hepatol Int       Date:  2020-07-07       Impact factor: 6.047

7.  Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study.

Authors:  Merel S Koedijk; Ben J M Heijmen; Bas Groot Koerkamp; Ferry A L M Eskens; Dave Sprengers; Jan-Werner Poley; Dik C van Gent; Luc J W van der Laan; Bronno van der Holt; François E J A Willemssen; Alejandra Méndez Romero
Journal:  BMJ Open       Date:  2018-10-15       Impact factor: 2.692

8.  Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma.

Authors:  Dingzhong Peng; Jiong Lu; Haijie Hu; Bei Li; Xiwen Ye; Nansheng Cheng
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

9.  A simple scoring system to predict early recurrence of Bismuth-Corlette type IV perihilar cholangiocarcinoma.

Authors:  Ding-Zhong Peng; Jiong Lu; Bei Li; Hai-Jie Hu; Xi-Wen Ye; Xian-Ze Xiong; Nan-Sheng Cheng
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-04-21

10.  Selective biliary occlusion in rodents: description of a new technique.

Authors:  Beate Richter; Constanze Sänger; Franziska Mussbach; Hubert Scheuerlein; Utz Settmacher; Uta Dahmen
Journal:  Innov Surg Sci       Date:  2022-06-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.